<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Rechtliche Hilfe für Alpha-1-Patienten | Alpha1 Deutschland</title>
	<atom:link href="https://alpha1-deutschland.org/en/themen/rechtliches/feed" rel="self" type="application/rss+xml" />
	<link>https://alpha1-deutschland.org/en/themen/rechtliches/</link>
	<description></description>
	<lastBuildDate>Fri, 21 Aug 2026 15:46:16 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updateperiod>
	hourly	</sy:updateperiod>
	<sy:updatefrequency>
	1	</sy:updatefrequency>
	<generator>https://wordpress.org/?v=7.1</generator>

<image>
	<url>https://alpha1-deutschland.org/wp-content/uploads/cropped-favicon-256x256-1-32x32.png</url>
	<title>Rechtliche Hilfe für Alpha-1-Patienten | Alpha1 Deutschland</title>
	<link>https://alpha1-deutschland.org/en/themen/rechtliches/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Infobroschüre: Schwerbehindertenausweis</title>
		<link>https://alpha1-deutschland.org/en/infobroschuere-schwerbehindertenausweis</link>
		
		<dc:creator><![CDATA[A1D-WebRedaktion]]></dc:creator>
		<pubDate>Mon, 01 Jun 2026 12:34:45 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Mobilität]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<guid ispermalink="false">https://alpha1-deutschland.org/?p=7213</guid>

					<description><![CDATA[<p>We have summarized everything about the severely disabled person&#039;s ID card at Alpha-1 in our current brochure, with the support of our advisory board member Nicole Scherhag. You can also find it at https://alpha1-deutschland.org/flyer</p>
<p>The post <a href="https://alpha1-deutschland.org/en/infobroschuere-schwerbehindertenausweis">Infobroschüre: Schwerbehindertenausweis</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<p>We have summarized everything about the severely disabled person&#039;s ID card at Alpha-1 in the current brochure with the support of our advisory board member Nicole Scherhag.</p>
<div class='w3eden wpdm_package_shortcode'><!-- WPDM Link Template: Default Template -->

<div class="link-template-default card mb-2">
    <div class="card-body">
        <div class="media">
            <div class="mr-3 img-48"><img decoding="async" class="wpdm_icon" alt="Icon" src="https://alpha1-deutschland.org/wp-content/plugins/download-manager/assets/file-type-icons/pdf.svg" /></div>
            <div class="media-body">
                <h3 class="package-title"><a href='https://alpha1-deutschland.org/en/download/behindertenausweis-infobroschuere'>Disability ID card information brochure</a></h3>
                <div class="text-muted text-small"><i class="fas fa-copy"></i> 1 file(s) <i class="fas fa-hdd ml-3"></i> 7.17 MB</div>
            </div>
            <div class="ml-3">
                <a class='wpdm-download-link download-on-click btn btn-link btn-xs'  rel='nofollow' href='#' data-downloadurl="https://alpha1-deutschland.org/en/download/behindertenausweis-infobroschuere?wpdmdl=7205&refresh=6a8c89237376c1787595043">Download</a>
            </div>
        </div>
    </div>
</div>

</div>
<p>or under <a class="_0ed2c049 _3a4138ef" href="https://alpha1-deutschland.org/en/flyer/" target="_blank" rel="noopener"><span class="eed719b3"><strong>https://alpha1-deutschland.org/flyer</strong></span></a></p><p>The post <a href="https://alpha1-deutschland.org/en/infobroschuere-schwerbehindertenausweis">Infobroschüre: Schwerbehindertenausweis</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Regelungen der Tourismusabgaben bei Schwerbehinderung, „Kurtaxe und Co“</title>
		<link>https://alpha1-deutschland.org/en/regelungen-der-tourismusabgaben-bei-schwerbehinderung-kurtaxe-und-co</link>
		
		<dc:creator><![CDATA[A1D-WebRedaktion]]></dc:creator>
		<pubDate>Thu, 12 Feb 2026 09:35:48 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Mobilität]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<category><![CDATA[Gebühren]]></category>
		<category><![CDATA[Kurabgabe]]></category>
		<category><![CDATA[Kurtaxe]]></category>
		<category><![CDATA[Schwerbehinderung]]></category>
		<category><![CDATA[Tourismus]]></category>
		<guid ispermalink="false">https://alpha1-deutschland.org/?p=7046</guid>

					<description><![CDATA[<p>Regulations regarding tourism taxes for people with severe disabilities: &quot;Visitor&#039;s tax and similar taxes&quot; Unfortunately, there is no nationwide overview of how tourism taxes (e.g., visitor&#039;s tax, guest tax, overnight tax/bed tax/tourist contribution) are regulated for people with severe disabilities in Germany, because...</p>
<p>The post <a href="https://alpha1-deutschland.org/en/regelungen-der-tourismusabgaben-bei-schwerbehinderung-kurtaxe-und-co">Regelungen der Tourismusabgaben bei Schwerbehinderung, „Kurtaxe und Co“</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<h1 style="font-weight: 400;"><strong>Regulations regarding tourism taxes for severely disabled persons</strong></h1>
<p style="font-weight: 400;"><strong>„&quot;Tourist tax and more&quot;“</strong></p>
<p style="font-weight: 400;">Unfortunately, there is no nationwide overview of how tourism taxes (e.g., visitor&#039;s tax, guest tax, overnight tax/bed tax/tourist contribution) are regulated for severely disabled people in Germany, as there is no uniform national regulation. Each municipality or city enacts its own bylaws.</p>
<p style="font-weight: 400;"><strong>Basic information: What are tourism taxes?</strong></p>
<p style="font-weight: 400;">In Germany, many <strong>Cities, towns and spas have local taxes</strong>, which concern tourist activities and stays. The most common forms are:</p>
<ul style="font-weight: 400;">
<li><strong>Tourist tax / visitor&#039;s tax / tourism levy (daily rate)</strong> – usually per person/day to finance tourist infrastructure and services.</li>
<li><strong>Accommodation tax / lodging tax / city tax / cultural promotion tax</strong> – often as <strong>Percentage of the accommodation price</strong>, e.g. in large cities.</li>
<li><strong>Tourism tax</strong> – is not necessarily collected directly from the guest, but usually from businesses that profit from tourism (e.g. holiday apartments).</li>
</ul>
<p style="font-weight: 400;"><strong>Severely disabled </strong><strong>–</strong><strong> General situation</strong></p>
<ol>
<li style="font-weight: 400;"><strong> Tourist tax / visitor&#039;s tax (per day/person)</strong></li>
</ol>
<p style="font-weight: 400;">In many municipalities, the statutes stipulate that <strong>Severely disabled persons may be fully or partially exempt or have to pay a reduced rate.</strong>. The specific details depend on the municipality:</p>
<ul style="font-weight: 400;">
<li>Exemption or reduction for certain disability symbols<br />
Often, the following applies: People with a degree of disability (GdB) of 80 or above, or with the markers &quot;B&quot; (accompaniment), &quot;aG&quot; (exceptional walking disability), &quot;Bl&quot; (blindness), &quot;H&quot; (helpless) are partially exempt or pay less.</li>
<li>Accompanying persons are usually also exempt if the disability ID card bears the symbol &quot;B&quot;.</li>
<li>In some towns, for example, the tourist tax is completely waived for the person affected and their accompanying person if their disability rating is 100.</li>
</ul>
<p style="font-weight: 400;"><strong>But:</strong> There are also places (e.g. on Rügen) that have changed their statutes so that even people with disabilities have to pay the normal tourist tax.</p>
<ol start="2">
<li style="font-weight: 400;"><strong> Accommodation tax / lodging tax (city tax)</strong></li>
</ol>
<p style="font-weight: 400;">This fee is levied by some cities (e.g. Hamburg, Berlin, Münster, Magdeburg, Mannheim) as a percentage of the accommodation price.<br />
A nationwide exemption for severely disabled persons is much less frequently explicitly provided for, because this tax often does not take into account &quot;tourist stays&quot; but overnight stays in general – thus also including business travelers.<br />
However, in some smaller municipalities there are exceptions for severely disabled people with certain distinguishing marks and their accompanying persons – if this is regulated in the statutes (e.g. severely disabled ≥ 80 % and accompanying person).</p>
<ol start="3">
<li style="font-weight: 400;"><strong> Tourism tax for businesses</strong></li>
</ol>
<p style="font-weight: 400;">This levy is primarily aimed at businesses that profit from tourism and is a business tax. Therefore, individuals – including tourists, even those with severe disabilities – are generally not eligible for personal exemptions, as the levy is paid by the business, not by the guest.</p>
<p style="font-weight: 400;"><strong>Important legal and practical information</strong></p>
<ul>
<li>There is no uniform regulation across Germany: Each municipality can define its own exceptions for severely disabled people.</li>
<li>Proof required: The exemption/reduction of the tourist tax is usually only recognized if the severely disabled person&#039;s ID card (especially with the codes &quot;B&quot;, &quot;aG&quot;, &quot;Bl&quot;, &quot;H&quot;) is presented at check-in or registration.</li>
<li>Accompanying persons: An accompanying person is only exempt if this is expressly stated in the statutes and noted in the identification card (e.g., symbol B).</li>
</ul>
<p style="font-weight: 400;"><strong>Recommendation for travelers</strong></p>
<p style="font-weight: 400;">Since the regulations vary so much, it&#039;s worth checking:</p>
<ol style="font-weight: 400;">
<li>Before starting your trip, check the tourist tax/tourism levy regulations of the respective municipality online.</li>
<li>Please have your disability ID card ready when booking or arriving (especially if it has the code &quot;B&quot; for accompaniment).</li>
<li>If you have any questions, please contact the accommodation provider or the local tourist information office directly.</li>
</ol>
<p style="font-weight: 400;"><p>The post <a href="https://alpha1-deutschland.org/en/regelungen-der-tourismusabgaben-bei-schwerbehinderung-kurtaxe-und-co">Regelungen der Tourismusabgaben bei Schwerbehinderung, „Kurtaxe und Co“</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Schwerbehindertenausweis mit Alpha-1-Antitrypsin-Mangel</title>
		<link>https://alpha1-deutschland.org/en/schwerbehindertenausweis-mit-alpha-1-antitrypsin-mangel</link>
		
		<dc:creator><![CDATA[A1D-WebRedaktion]]></dc:creator>
		<pubDate>Sun, 04 Jan 2026 17:25:05 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<category><![CDATA[SB-Ausweis]]></category>
		<category><![CDATA[Schwerbehinderung]]></category>
		<guid ispermalink="false">https://alpha1-deutschland.org/?p=7020</guid>

					<description><![CDATA[<p>Disability ID card with Alpha-1 Antitrypsin Deficiency. Click here for the webinar recording on the topic of severe disability from CSL Behring in cooperation with Alpha1 Germany. Below we would like to inform you about the topic of severe disability...</p>
<p>The post <a href="https://alpha1-deutschland.org/en/schwerbehindertenausweis-mit-alpha-1-antitrypsin-mangel">Schwerbehindertenausweis mit Alpha-1-Antitrypsin-Mangel</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<h1 style="font-weight: 400;"><span style="color: #004267;">Disability ID card with alpha-1 antitrypsin deficiency</span></h1>
<p style="font-weight: 400;"><a href="https://players.brightcove.net/5838291723001/default_default/index.html?videoId=6341486308112">Click here to access the webinar recording on the topic of severe disability from CSL Behring in cooperation with Alpha1 Germany.</a></p>
<p>&nbsp;</p>
<p style="font-weight: 400;">Below, we would like to inform you about the topic of severe disability and provide you with as much information as possible. Please feel free to contact us if you have any further questions.</p>
<h2><span style="color: #004267;"><strong>What is a severely disabled person&#039;s ID card?</strong></span></h2>
<p style="font-weight: 400;"><strong> </strong>The severely disabled person&#039;s ID card is a credit card-sized document that provides information about the holder&#039;s degree of disability. This is referred to as the degree of disability (GdB). In everyday language, it is usually expressed as a percentage (for example, &quot;I have a 70% severe disability&quot;).</p>
<p style="font-weight: 400;">A severely disabled person&#039;s ID card is issued for a disability rating (GdB) of 50 or higher. For ratings below 50, only a notification is issued.</p>
<p style="font-weight: 400;">In addition, the disability card may contain certain symbols indicating specific limitations. For individuals with alpha-1 antitrypsin deficiency, the symbol &quot;G&quot; is often relevant. This symbol indicates that mobility in road traffic is significantly restricted – whether due to shortness of breath or limited walking ability that makes movement difficult. The symbol &quot;G&quot; is noted on the back of the card along with the degree of disability (GdB).</p>
<p style="font-weight: 400;">There are other distinguishing features; here are the most important ones:</p>
<table style="font-weight: 400; height: 942px;" width="876">
<tbody>
<tr>
<td width="302"><strong>Distinguishing mark</strong></td>
<td width="302"><strong>Meaning</strong></td>
</tr>
<tr>
<td width="302">G</td>
<td width="302">Severely mobility impaired</td>
</tr>
<tr>
<td width="302">aG</td>
<td width="302">Exceptional walking disability</td>
</tr>
<tr>
<td width="302">B</td>
<td width="302">Entitlement to bring along an accompanying person</td>
</tr>
<tr>
<td width="302">H</td>
<td width="302">helplessness</td>
</tr>
<tr>
<td width="302">Bl</td>
<td width="302">Blind</td>
</tr>
<tr>
<td width="302">Gl</td>
<td width="302">Deafness</td>
</tr>
<tr>
<td width="302">RF</td>
<td width="302">Exemption or reduction of broadcasting fees</td>
</tr>
<tr>
<td width="302">TBl</td>
<td width="302">Deafblind</td>
</tr>
</tbody>
</table>
<p style="font-weight: 400;">The validity period is also noted on the ID card, which is located below the holder&#039;s photo.</p>
<p style="font-weight: 400;"><strong> </strong></p>
<h2><span style="color: #004267;"><strong>How do you obtain a severely disabled person&#039;s ID card?</strong></span></h2>
<p style="font-weight: 400;">To have the degree of disability assessed, an application must be submitted. This application is filed with the responsible authority. Which authority is responsible depends on the federal state. It is usually the district office or the social welfare office.</p>
<p style="font-weight: 400;">You can find out which office is responsible at your local citizens&#039; registration office or online. The addresses of the relevant authorities are listed there. Application forms are also available online. For example, you can find them using a search engine by entering &quot;application for severe disability + Rhineland-Palatinate&quot;.</p>
<p style="font-weight: 400;">Alternatively, application forms can be obtained directly from the responsible authority or, in many places, from the citizens&#039; office.</p>
<p style="font-weight: 400;">You also need a passport photo.</p>
<p style="font-weight: 400;"><strong>Let&#039;s go!</strong></p>
<p style="font-weight: 400;">It is recommended that you first carefully read the instructions and information sheet included with the application. It is also helpful to gather any existing medical documents, such as reports, doctor&#039;s letters, hospital reports, rehabilitation assessments, laboratory results, or X-ray reports. Other documents, such as medical bills from private patients, may also be useful.</p>
<p style="font-weight: 400;">If possible, it is advisable to attach copies of relevant documents – especially from the last two years – to the application. However, if no documents are available, a complete list of all health limitations or illnesses is sufficient. In this case, the processing time may be longer, as the necessary medical records must first be requested from the treating physicians listed.</p>
<p style="font-weight: 400;">The application must list all physical, mental, and psychological health impairments that have existed (or will exist) for at least six months and that are to be considered for determining the degree of disability (GdB). This includes not only alpha-1 antitrypsin deficiency or impaired lung function, but also all other existing illnesses and resulting functional limitations. Complete information is essential for an accurate assessment of the GdB.</p>
<p style="font-weight: 400;">Furthermore, it can be helpful to include a supplementary description of the individual&#039;s health situation with the application. In particular, describing limitations on especially stressful days and providing concrete, vivid examples can help to convey the most realistic picture possible of the actual impairments. The determination of the degree of disability (GdB) is not about diagnoses, but about the impact of the illnesses on the affected person&#039;s daily life. These should be presented clearly and comprehensibly on a separate sheet.</p>
<p style="font-weight: 400;">Furthermore, all treating physicians and hospitals must be named and released from their duty of confidentiality so that the responsible authority can obtain the necessary medical information. It is advisable to inform the respective treating physicians in advance that an inquiry from the authority may be made in order to expedite the processing as much as possible.</p>
<p style="font-weight: 400;">If the space provided in the application form for listing the treating institutions is insufficient, the relevant information can be added on a separate sheet and attached to the application. Care should be taken to ensure that no one is overlooked.</p>
<p style="font-weight: 400;">Once fully completed, the application, including the required passport photo, must be sent to the relevant authority; registered mail is recommended. Processing may then take up to six months. If no confirmation of receipt or processing is received within approximately four weeks, it is advisable to contact the relevant authority in writing.</p>
<p style="font-weight: 400;">If you have any uncertainties or questions about completing the application, you can seek additional professional support. This is offered, for example, by the social welfare association VdK or the social welfare association of Germany (SoVD). Membership in the respective association is usually required for this. Alternatively, the free consultation service of the Supplementary Independent Participation Advisory Service (Supplementary Independent Participation Advisory Service) is available.<a href="https://alpha1-deutschland.org/en/alpha-1-glossar/">EUTB</a>) available.</p>
<h2><span style="color: #004267;"><strong>How is the degree of disability (GdB) determined?</strong></span></h2>
<p style="font-weight: 400;">The responsible authority generally does not conduct a personal examination of the applicant, but rather makes its decision based on the available files. The decisive factor here is the German Ordinance on Medical Assessment for Disability Benefits (VersMedV) and the principles of medical assessment contained therein. These establish corresponding assessment criteria for a wide range of possible health impairments in the form of degrees of disability (GdB) or degrees of impairment.</p>
<p style="font-weight: 400;">If several health impairments are present simultaneously (e.g., a lung dysfunction, a depressive disorder, and an orthopedic impairment), the individual disability ratings are not added together. Instead, an overall assessment is conducted, examining the extent to which the individual functional impairments influence each other and their combined effect. The starting point for the assessment is always the most severe impairment with the highest individual disability rating; the other limitations are then considered in relation to this primary impairment.</p>
<p style="font-weight: 400;">In practice, the determined results may not always be readily comprehensible. If the degree of disability (GdB) is perceived as too low, an appeal should be filed within the prescribed time limit.</p>
<p style="font-weight: 400;">Support can be obtained from the aforementioned advice centers.</p>
<p style="font-weight: 400;">For individuals with alpha-1 antitrypsin deficiency, the regulations in Chapter 8 (Chest, lower airways and lungs) of the German Social Code, Book V (SGB V) are particularly important. Furthermore, depending on the individual&#039;s health situation, other chapters, such as Chapter 9 (Heart and circulatory system), may also be relevant.</p>
<p style="font-weight: 400;">The German Social Code, Book IX (SGB IX), assigns specific assessment frameworks in the form of disability ratings (GdB values) to various health impairments. In this context, the term &quot;degree of impairment&quot; (GdS) is also frequently used, which describes the severity of the respective health impairment. GdS and GdB are assessed according to the same principles.</p>
<p style="font-weight: 400;">The following differentiation is provided in the principles of social medicine under chapter 8.3 „Diseases of the respiratory organs with permanent impairment of lung function“:</p>
<p style="font-weight: 400;"><strong>Easy degree</strong><br />
There is excessive shortness of breath during moderate exertion (e.g., brisk walking at 5–6 km/h or moderate physical work). Static and dynamic lung function test results are up to one-third below predicted values; blood gas values are within the normal range.<br />
→ GdS: 20–40</p>
<p style="font-weight: 400;"><strong>Intermediate level</strong><br />
Shortness of breath occurs even during light everyday exertion (e.g., walking at 3–4 km/h, climbing stairs to one floor, or light physical work). Static and dynamic lung function test results are up to two-thirds below predicted values; partial respiratory insufficiency is present.<br />
→ GdS: 50–70</p>
<p style="font-weight: 400;"><strong>Severe degree</strong><br />
Shortness of breath occurs even with minimal exertion or at rest. Static and dynamic lung function test results are more than two-thirds below predicted values; this indicates global respiratory failure.<br />
→ GdS: 80–100</p>
<p style="font-weight: 400;">Following a lung transplant, the healing process must first be monitored. For a period of two years, the degree of disability is generally assessed at 100. Even in cases of favorable recovery, a degree of disability of at least 70 must subsequently be assigned. This regulation can be found in Chapter 8.4 of the Principles of Disability Assessment.</p>
<p style="font-weight: 400;">Furthermore, other conditions, such as sleep apnea syndrome, can be included in the overall assessment of the degree of disability (see Chapter 8.7).</p>
<p style="font-weight: 400;"><strong> </strong></p>
<h2><span style="color: #004267;"><strong>What advantages do I have with a severely disabled person&#039;s ID card?</strong></span></h2>
<p style="font-weight: 400;">The benefits of the severely disabled person&#039;s ID card are referred to as compensation for disadvantages, as they are intended to offset existing limitations.</p>
<p style="font-weight: 400;">Here you will find two very clear overviews, one showing the compensation for disadvantages according to the degree of disability and the other showing the compensation for disadvantages for the respective disability markers.</p>
<p style="font-weight: 400;"><a href="https://www.betanet.de/files/pdf/nachteilsausgleiche-gdb.pdf">Disability-dependent compensation measures</a></p>
<p style="font-weight: 400;"><a href="https://www.betanet.de/files/pdf/nachteilsausgleiche-merkzeichen.pdf">Disability-related compensation measures</a></p>
<h2><span style="color: #004267;"><strong>My application for disability status was rejected, or in my opinion the degree of disability is too low – what now?</strong></span></h2>
<p style="font-weight: 400;">You now have one month to file an objection. An objection will prompt the responsible authority to review the decision. To meet the deadline, the objection must be received by the issuing authority within one month.</p>
<p style="font-weight: 400;">The contradiction could be phrased as follows:</p>
<p style="font-weight: 400;">„&quot;I hereby object to the decision dated… with file number… within the prescribed time limit. Please send me all information that led to your decision so that I can base my justification on it. A detailed justification will follow.&quot;“</p>
<p style="font-weight: 400;">Don&#039;t forget the date and signature!</p>
<p style="font-weight: 400;">This saves time and provides the opportunity to develop one&#039;s own argument in a targeted manner, to explain which aspects were not taken into account or how they should have been evaluated.</p>
<p style="font-weight: 400;">Should the application be rejected again, it is possible to file a lawsuit with the Social Court if you wish to pursue the matter further. The one-month deadline must also be observed in this case. Support can again be sought from a social welfare organization or the EUTB (Independent Participation Advisory Service).</p>
<h2 style="font-weight: 400;"><span style="color: #004267;"><strong>In a nutshell: Tips for submitting an application </strong></span></h2>
<ul>
<li>Give <strong>all diseases</strong> and impairments. Also describe the burdensome aspects. <strong>Effects of the necessary treatments</strong>. Use an additional sheet and describe in detail the impact of the illness and treatment on your entire life (e.g., family life, social life, mobility, partnership, sexuality, eating, sleeping, managing the household, etc.).</li>
<li>List the doctors and clinics who are currently best informed about your illness(es) and release them from their duty of confidentiality (this is already included in the application).</li>
<li>Discuss the application with your treating physician so that, in addition to the diagnoses, the effects of the illness and/or the therapy are also described in detail.</li>
<li>Please attach all relevant medical documents you have to your application.</li>
<li>Please include a passport photo (name and date of birth on the back) for identification purposes.</li>
</ul>
<p><em>Authors: Heike Isensee and Nicole Scherhag</em></p>
<p style="font-weight: 400;"><strong>Note: </strong></p>
<p style="font-weight: 400;">At Alpha1 Germany, we have Nicole Scherhag as an advisor who is knowledgeable about social law and its intricacies. Please feel free to contact her with any questions. Her contact details can be found on our website in the relevant section. <a href="https://alpha1-deutschland.org/en/wissenschaftlicher-beirat-und-vorstand/" target="_blank" rel="noopener">„&quot;About Us&quot;“</a> to find.</p><p>The post <a href="https://alpha1-deutschland.org/en/schwerbehindertenausweis-mit-alpha-1-antitrypsin-mangel">Schwerbehindertenausweis mit Alpha-1-Antitrypsin-Mangel</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Phasen der Arzneimittelzulassung</title>
		<link>https://alpha1-deutschland.org/en/phasen-der-arzneimittelzulassung</link>
		
		<dc:creator><![CDATA[Redaktion Alpha1 Deutschland e.V.]]></dc:creator>
		<pubDate>Mon, 08 Jan 2024 12:44:16 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<guid ispermalink="false">https://alpha1-deutschland.org/?p=5810</guid>

					<description><![CDATA[<p>The post <a href="https://alpha1-deutschland.org/en/phasen-der-arzneimittelzulassung">Phasen der Arzneimittelzulassung</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a8c89238c4c5"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row top-level full-width-section"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				<div class="vc_separator wpb_content_element vc_separator_align_center vc_sep_width_100 vc_sep_border_width_5 vc_sep_pos_align_center vc_sep_color_grey wpb_content_element vc_separator-has-text" ><span class="vc_sep_holder vc_sep_holder_l"><span class="vc_sep_line"></span></span><h4>Author</h4><span class="vc_sep_holder vc_sep_holder_r"><span class="vc_sep_line"></span></span>
</div>
<div class="wpb_text_column wpb_content_element" >
	<p style="font-weight: 400;"><strong>Heinz Stutzenberger, Alpha1 Deutschland eV, as published in <a href="https://alpha1-deutschland.org/en/alpha1-journal/">Alpha1 Journal 1/2022</a>.</strong></p>
</div>



<div class="divider-wrap" data-alignment="default"><div style="margin-top: 25px; height: 5px; margin-bottom: 25px;" data-width="100%" data-animate="" data-animation-delay="" data-color="default" class="divider-border"></div></div>
<div class="wpb_text_column wpb_content_element" >
	<p>Under the &quot;Research &amp; Studies&quot; section of our website, you will usually find several calls for participation in scientific studies. These are typically the third and final phase of a standardized procedure for the approval of new medications (a fourth phase after approval is also possible, see below). In this Phase 3, the safety and efficacy of new drugs are demonstrated. It builds on studies in earlier phases, and a Phase 3 study is only initiated if the results of the preceding study phases are positive.</p>
<p>The content of each study phase is as follows.<sup>1,2</sup>:</p>
<h2><span style="color: #004267;">Phase 1: Compatibility and safety assessment</span></h2>
<ul>
<li>first-time use of the drug in humans to study tolerability, safety and behavior of the active ingredient in the body</li>
<li>Typically up to 100 study participants who are either healthy or for whom there is no other therapy option (anymore).</li>
<li>This phase lasts weeks to months.</li>
<li>Because of the risk associated with the first application in humans, participants are often paid considerable fees.</li>
</ul>
<h2><span style="color: #004267;">Phase 2: Verification of effectiveness, determination of appropriate dosages</span></h2>
<ul>
<li>In a strictly defined group of up to 500 patients, it will be tested whether and at what dosage the drug is effective for treating the disease.</li>
<li>This phase also lasts weeks to months.</li>
<li>Typically, no fees are paid for participation in this phase.</li>
</ul>
<h2><span style="color: #004267;">Phase 3: Proof of efficacy and safety</span></h2>
<ul>
<li>Investigation of the efficacy and tolerability of the preparation and the evaluation of its benefits, also with regard to the frequency and severity of side effects.</li>
<li>A larger group of participants, often over 1,000 patients, makes it possible to better assess even less frequent side effects.</li>
<li>This phase lasts months to years.</li>
<li>It is often conducted as a randomized, double-blind study, in which
<ul>
<li>The participants will be randomly divided into two groups.</li>
<li>Only one group receives the drug, while the other receives a placebo.</li>
<li>Neither the study participants nor the study assistants (the participating doctors) know who receives the medication or the placebo.</li>
</ul>
</li>
<li>Participants will not receive a fee; there will be no financial incentives for participation.</li>
<li>After this phase, the subsequent steps look like this:
<ul>
<li>an intensive evaluation of the present and further study results</li>
<li>the review of the results by other expert bodies</li>
<li>and finally the application for approval of the new drug to the competent authority.</li>
</ul>
</li>
<li>These phase 3 trials are the ones of interest to AATM patients.</li>
</ul>
<h2><span style="color: #004267;">Phase 4: Long-term observation to detect side effects</span></h2>
<ul>
<li>This only occurs after approval and testing on a large number of patients (often over 1,000).</li>
<li>It serves to identify rare side effects or interactions with other medications.</li>
<li>It may also consider specific patient groups, e.g., a particular age group, people with specific medical conditions, and similar factors.</li>
</ul>
<p>The most important points of each study phase are summarized again in the table below:</p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a8c89238def4"  data-column-margin="default" data-midnight="dark" data-top-percent="2%"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: calc(100vw * 0.02); padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				<div class="img-with-aniamtion-wrap" data-max-width="100%" data-max-width-mobile="default" data-shadow="none" data-animation="none" >
      <div class="inner">
        <div class="hover-wrap"> 
          <div class="hover-wrap-inner">
            <a href="https://alpha1-deutschland.org/wp-content/uploads/Uebersicht-Phasen-Arzneimittelzulassung.jpg" class="pp">
              <img fetchpriority="high" decoding="async" class="img-with-animation skip-lazy" data-delay="0" height="974" width="1677" data-animation="none" src="https://alpha1-deutschland.org/wp-content/uploads/Uebersicht-Phasen-Arzneimittelzulassung.jpg" alt="Übersicht: Die vier Phasen der Arzneimittelzulassung" srcset="https://alpha1-deutschland.org/wp-content/uploads/Uebersicht-Phasen-Arzneimittelzulassung.jpg 1677w, https://alpha1-deutschland.org/wp-content/uploads/Uebersicht-Phasen-Arzneimittelzulassung-300x174.jpg 300w, https://alpha1-deutschland.org/wp-content/uploads/Uebersicht-Phasen-Arzneimittelzulassung-1024x595.jpg 1024w, https://alpha1-deutschland.org/wp-content/uploads/Uebersicht-Phasen-Arzneimittelzulassung-768x446.jpg 768w, https://alpha1-deutschland.org/wp-content/uploads/Uebersicht-Phasen-Arzneimittelzulassung-1536x892.jpg 1536w" sizes="(max-width: 1677px) 100vw, 1677px" />
            </a>
          </div>
        </div>
         
      </div>
      </div>
			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a8c89238f691"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element" >
	<p>As mentioned previously, Phase 3 trials are of interest to AATM patients, usually conducted as randomized, double-blind studies. Anyone seriously interested in participating in a trial will first review the &quot;Patient Information and Informed Consent Form&quot; with their attending physician. This ensures that<sup>1</sup></p>
<ul>
<li>The potential participant fully understands the clinical trial, including all procedures, possible side effects, and other risks that may be associated with participating in or conducting the study.</li>
<li>he is aware of his responsibility as a participant in the clinical trial</li>
<li>all his questions regarding the clinical trial will be answered</li>
<li>He knows that he can leave the clinical trial at any time without giving a reason.</li>
</ul>
<h2><span style="color: #004267;">Relevant questions that should be clarified include:<sup>1</sup>:</span></h2>
<ul>
<li>What is the specific goal of the clinical trial?</li>
<li>How is the study planned to proceed?</li>
<li>What accompanying examinations are planned?</li>
<li>Who is funding the study?</li>
<li>Will the participant incur any costs by taking part in the study?</li>
<li>Is there any compensation for expenses?</li>
<li>Has participant insurance been taken out?</li>
<li>How much time is required for participation?</li>
<li>What obligations are associated with participating in the study?</li>
<li>Is longer follow-up required after the study is completed?</li>
<li>What are the benefits and risks of participating in the study compared to existing treatment methods?</li>
<li>What experience is already available for the new therapy method?</li>
<li>What side effects can be expected?</li>
<li>Who is responsible for student support?</li>
<li>Who can be contacted in case of an emergency or if questions arise?</li>
<li>What data is collected, processed, and stored?</li>
<li>What restrictions should be expected at the beginning or during the clinical trial (e.g., no pregnancy, no alcohol)?</li>
<li>What happens if the study is terminated prematurely?</li>
<li>If necessary: how can the treatment be continued after the end of the study?</li>
</ul>
<h2><span style="color: #004267;">Participation in clinical trials: Flexibility and responsibility in the decision-making process</span></h2>
<p>It is reassuring to know that participants can withdraw from the study at any time without giving a reason and without incurring further disadvantages. However, it is important to note that these studies incur very high costs for the initiating pharmaceutical company, and the withdrawal of participants can reduce the study&#039;s validity. Therefore, withdrawal should not be taken lightly or factored into the decision to participate. Typically, in the event of withdrawal, the organizers will ask for the reasons and, in particular, whether these are related to the (side) effects of the medication. The withdrawing participant can answer these questions, but is not obligated to do so.</p>
<p>Participants should also be aware that the pharmaceutical company conducting the study aims to generate revenue and profit through drug approval. However, this appears to be a legitimate approach, as it is the only way to ensure research into new drugs, especially those for rare diseases like AATD. Government agencies no longer conduct drug development themselves, but at most provide funding for basic research and Phase 1 and 2 clinical trials.<sup>3</sup></p>
<h2><span style="color: #004267;">Participation in Phase 3 trials: Recognizing opportunities and keeping an eye on risks</span></h2>
<p>However, this aspect also provides an additional level of security for study participants, as pharmaceutical companies go to great lengths to avoid liability claims arising from the development and distribution of unsuitable medications. Despite the unavoidable residual risk associated with novel drugs, we believe that participation in Phase 3 trials offers more opportunities than risks, and we encourage you to seriously consider participating in trials for which you are eligible.</p>
<p>Should someone, after careful consideration, decide to participate in a Phase 3 double-blind study, especially hoping to finally receive an effective drug to control or prevent the progression of their disease, their chances of improved treatment are naturally only 50%, since they could also be assigned to the placebo group with exactly this probability.</p>
<p>But even then, participation still brings him significant advantages, e.g.</p>
<ul>
<li>an intensified monitoring of his health and disease progression through the study-accompanying examinations</li>
<li>the awareness of having made a relevant contribution for those patients who will benefit from the improved treatment after approval.</li>
<li>possibly also an intensification of the body&#039;s self-healing powers as a result of the conscious decision to actively do something for its recovery and to be supported by caring, empathetic companions.<sup>4</sup></li>
</ul>
<h3>Sources</h3>
<ol>
<li><a href="https://www.jnjwithme.de/de-de/forschung-und-entwicklung#1.-Wie-wird-ein-neues-Medikament-entwickelt-" target="_blank" rel="noopener">janssenwithme.de</a>, Last accessed January 24, 2024.</li>
<li><a href="https://www.cslbehring.com/r-and-d/clinical-studies-at-csl-behring/what-is-a-clinical-trial" target="_blank" rel="noopener">csl.com</a>, Last accessed January 24, 2024.</li>
<li><a href="https://www.bmbf.de/bmbf/shareddocs/bekanntmachungen/de/2021/03/3481_bekanntmachung.html" target="_blank" rel="noopener">bmbf.de</a>, Last accessed January 24, 2024.</li>
<li>Mende, Annette: <a href="https://www.pharmazeutische-zeitung.de/ausgabe-51522012/scheinmedikament-mit-echter-wirkung/" target="_blank" rel="noopener">Placebottle-medicine with real effects</a>, Pharmaceutical Journal, Issue 51/52/2012.</li>
</ol>
</div>




			</div> 
		</div>
	</div> 
</div></div><p>The post <a href="https://alpha1-deutschland.org/en/phasen-der-arzneimittelzulassung">Phasen der Arzneimittelzulassung</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Kräfte bündeln – Gemeinsam mehr erreichen!</title>
		<link>https://alpha1-deutschland.org/en/schwerbehindertenrecht-bei-alpha1</link>
		
		<dc:creator><![CDATA[Redaktion Alpha1 Deutschland e.V.]]></dc:creator>
		<pubDate>Fri, 13 Oct 2023 11:58:18 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Alpha1-Journal]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<guid ispermalink="false">https://alpha1-deutschland.org/?p=6668</guid>

					<description><![CDATA[<p>The post <a href="https://alpha1-deutschland.org/en/schwerbehindertenrecht-bei-alpha1">Kräfte bündeln – Gemeinsam mehr erreichen!</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a8c892399088"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row full-width-section"  style="padding-top: 0px; padding-bottom: 50px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				<div class="vc_separator wpb_content_element vc_separator_align_center vc_sep_width_100 vc_sep_border_width_5 vc_sep_pos_align_center vc_sep_color_grey wpb_content_element vc_separator-has-text" ><span class="vc_sep_holder vc_sep_holder_l"><span class="vc_sep_line"></span></span><h4>Author</h4><span class="vc_sep_holder vc_sep_holder_r"><span class="vc_sep_line"></span></span>
</div>
<div class="wpb_text_column wpb_content_element" >
	<p style="font-weight: 400;"><strong>Marion Wilkens and Nicole Scherhag, as appeared in <a href="https://alpha1-deutschland.org/en/alpha1-journal/">Alpha1 Journal 2/2023</a>.</strong></p>
</div>



<div class="divider-wrap" data-alignment="default"><div style="margin-top: 25px; height: 5px; margin-bottom: 25px;" data-width="100%" data-animate="" data-animation-delay="" data-color="default" class="divider-border"></div></div>
<div class="wpb_text_column wpb_content_element" >
	<p>Dear Alpha-1 patients, dear relatives,</p>
<p>Living with a chronic illness can mean facing challenges on many fronts, including in disability law. The principles of disability assessment stipulate that, in the case of lung disease, the degree of disability is based on the impairment of lung function. This is not fair to everyone, and often we suffer from multiple illnesses whose varying effects are not adequately assessed. Furthermore, the psychological burdens also need to be taken into account.</p>
<p>The idea of pooling our experience, resources and knowledge was born during our webinar series on social law.</p>
<h2><span style="color: #004267;">We need you for this!</span></h2>
<p>Please send us your successful applications, appeals, and legal letters concerning severe disability. Your submissions will be reviewed exclusively by myself, Marion Wilkens, and social law expert Nicole Scherhag. Ms. Scherhag is bound by confidentiality. You can redact all personal details beforehand. Alternatively, you are welcome to send us the documents unredacted. We will then extract the relevant arguments and rewrite them in such a way that they can no longer be traced back to you.</p>
<p>Overall, we aim to develop suitable wording for people with Alpha-1 disorder and make it available to others affected. This will be done exclusively within the context of consultations in a self-help setting. Naturally, the templates will be individually tailored to each person.</p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a8c89239a36b"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				<div class="divider-wrap" data-alignment="center"><div style="margin-top: 25px; width: 20%; height: 2px; margin-bottom: 25px;" data-width="20%" data-animate="" data-animation-delay="" data-color="accent-color" class="divider-small-border"></div></div><p style="font-size: 30px;color: #004267;line-height: 2;text-align: center" class="vc_custom_heading vc_do_custom_heading" >Please send your documents to:<br />
sb-antraege@alpha1-deutschland.org</p><div class="divider-wrap" data-alignment="center"><div style="margin-top: 25px; width: 20%; height: 2px; margin-bottom: 25px;" data-width="20%" data-animate="" data-animation-delay="" data-color="accent-color" class="divider-small-border"></div></div>
			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a8c89239b76a"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element" >
	<p>You can also send us photos via SMS or WhatsApp (0179 69 33 068).</p>
<p>Thank you for your support!</p>
</div>




			</div> 
		</div>
	</div> 
</div></div><p>The post <a href="https://alpha1-deutschland.org/en/schwerbehindertenrecht-bei-alpha1">Kräfte bündeln – Gemeinsam mehr erreichen!</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Webinar-Reihe: Alles, was (Sozial)Recht ist!</title>
		<link>https://alpha1-deutschland.org/en/webinar-reihe-alles-was-sozialrecht-ist</link>
		
		<dc:creator><![CDATA[Redaktion Alpha1 Deutschland e.V.]]></dc:creator>
		<pubDate>Fri, 13 Oct 2023 11:53:17 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Alpha1-Journal]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<guid ispermalink="false">https://alpha1-deutschland.org/?p=6662</guid>

					<description><![CDATA[<p>The post <a href="https://alpha1-deutschland.org/en/webinar-reihe-alles-was-sozialrecht-ist">Webinar-Reihe: Alles, was (Sozial)Recht ist!</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a8c8923a025e"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row full-width-section"  style="padding-top: 0px; padding-bottom: 50px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				<div class="vc_separator wpb_content_element vc_separator_align_center vc_sep_width_100 vc_sep_border_width_5 vc_sep_pos_align_center vc_sep_color_grey wpb_content_element vc_separator-has-text" ><span class="vc_sep_holder vc_sep_holder_l"><span class="vc_sep_line"></span></span><h4>Author</h4><span class="vc_sep_holder vc_sep_holder_r"><span class="vc_sep_line"></span></span>
</div>
<div class="wpb_text_column wpb_content_element" >
	<p style="font-weight: 400;"><strong>Alpha1 Germany eV, as published in <a href="https://alpha1-deutschland.org/en/alpha1-journal/">Alpha1 Journal 2/2023</a>.</strong></p>
</div>



<div class="divider-wrap" data-alignment="default"><div style="margin-top: 25px; height: 5px; margin-bottom: 25px;" data-width="100%" data-animate="" data-animation-delay="" data-color="default" class="divider-border"></div></div>
<div class="wpb_text_column wpb_content_element" >
	<p>The first webinar series on the topic of &quot;Everything that is (Social) Law!&quot; started on September 6, 2023, and will run for a total of five sessions, always on a Wednesday evening, once a month. Our speaker and expert on social law, Nicole Scherhag, will be supported in the webinars by our moderators Prof. Dr. Rembert Koczulla and Marion Wilkens.</p>
<p>The past three webinars have covered current topics in detail:</p>
<ol>
<li>The webinar on September 6, 2023, entitled &quot;Applications in Social Law,&quot; addressed common pitfalls in the application process for social law benefits. Potential errors and frequent problems were highlighted to help participants avoid them. Furthermore, tips and tricks were provided on how to successfully submit applications under social law. This included guidance on correctly formulating the application, selecting the relevant documents, and adhering to deadlines. Additionally, the topic of rehabilitation was discussed, explaining the various aspects and options for rehabilitation within the framework of social law.</li>
<li>The webinar on October 4, 2023, entitled &quot;Health Insurance Benefits,&quot; discussed the services that can be covered by health insurance. Various aspects of healthcare and rehabilitation for which health insurance can provide financial support were addressed. Another topic of the webinar was home self-therapy. Participants learned what to consider when conducting therapy at home and received tips to ensure safe and effective home self-therapy.</li>
<li>The webinar on November 8, 2023, entitled &quot;Severe Disability,&quot; focused on the topic of &quot;Special Considerations for People with Severe Disabilities.&quot; The webinar explained various aspects to consider in connection with a severe disability. A key point was the application process for recognition of a severe disability. The webinar explained how to submit such an application and what documents are required. Furthermore, it clarified the different criteria used to determine the degree of disability (GdB). The webinar also discussed the various disability-related symbols that a person with a severe disability can apply for. These symbols serve to grant certain compensatory measures, such as a parking permit for people with mobility impairments or an accompanying person on public transportation. The webinar also presented the various compensatory measures that people with severe disabilities can claim. These include, for example, tax breaks, financial support for the purchase of assistive devices, and additional vacation time. In summary, the webinar provided a comprehensive overview of the special features of severe disabilities and informed participants about their rights and options.</li>
</ol>
<p><a href="https://www.alpha1-mangel.de/webinar" target="_blank" rel="noopener">All webinars were recorded and can be accessed online. </a></p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a8c8923a14e9"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 50px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element" >
	<h2><span style="color: #004267;">Marion Wilkens, Nicole Scherhag and Prof. Dr. Rembert Koczulla</span></h2>
</div>



<div class="divider-wrap" data-alignment="default"><div style="height: 10px;" class="divider"></div></div>
	<div class="wpb_gallery wpb_content_element clearfix">
		<div class="wpb_wrapper"><div class="wpb_gallery_slidesflickity_static_height_style" data-onclick="link_no" data-interval="5"><style>.wpb_gallery_slidesflickity_static_height_style .nectar-flickity.instace-6a8c8923a2926:not(.masonry) .flickity-slider .cell img {
      height: 500px;
    }
    @media only screen and (max-width: 1300px) {
      .wpb_gallery_slidesflickity_static_height_style .nectar-flickity.instace-6a8c8923a2926:not(.masonry) .flickity-slider .cell img {
        height: 400px;
      }
    }
    @media only screen and (max-width: 1000px) {
      .wpb_gallery_slidesflickity_static_height_style .nectar-flickity.instace-6a8c8923a2926:not(.masonry) .flickity-slider .cell img {
        height: 350px;
      }
    }
    @media only screen and (max-width: 690px) {
      .wpb_gallery_slidesflickity_static_height_style .nectar-flickity.instace-6a8c8923a2926:not(.masonry) .flickity-slider .cell img {
        height: 300px;
      }
    }</style><div class="nectar-flickity not-initialized instace-6a8c8923a2926" role="region" aria-roledescription="carousel" aria-label="Image gallery"  data-touch-icon-color="default" data-drag-scale="" data-overflow="hidden" data-wrap="wrap" data-spacing="default" data-shadow="none" data-autoplay="" data-autoplay-dur="" data-free-scroll="" data-controls="pagination"><div class="flickity-viewport"> <div class="flickity-slider"><div class="cell" data-lazy="false"><img decoding="async" width="1024" height="580" src="https://alpha1-deutschland.org/wp-content/uploads/Alpha1_Marion-Wilkens-1024x580.jpg" class="skip-lazy nectar-lazy attachment-large" alt="" title="Alpha1_Marion-Wilkens" srcset="https://alpha1-deutschland.org/wp-content/uploads/Alpha1_Marion-Wilkens-1024x580.jpg 1024w, https://alpha1-deutschland.org/wp-content/uploads/Alpha1_Marion-Wilkens-300x170.jpg 300w, https://alpha1-deutschland.org/wp-content/uploads/Alpha1_Marion-Wilkens-768x435.jpg 768w, https://alpha1-deutschland.org/wp-content/uploads/Alpha1_Marion-Wilkens.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></div><div class="cell" data-lazy="false"><img decoding="async" width="1024" height="580" src="https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Nicole-Scherhag-1024x580.jpg" class="skip-lazy nectar-lazy attachment-large" alt="" title="Alpha1-Nicole-Scherhag" srcset="https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Nicole-Scherhag-1024x580.jpg 1024w, https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Nicole-Scherhag-300x170.jpg 300w, https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Nicole-Scherhag-768x435.jpg 768w, https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Nicole-Scherhag.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></div><div class="cell" data-lazy="false"><img decoding="async" width="1024" height="580" src="https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Prof-Dr-Koczulla-1024x580.jpg" class="skip-lazy nectar-lazy attachment-large" alt="" title="Alpha1-Prof-Dr-Koczulla" srcset="https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Prof-Dr-Koczulla-1024x580.jpg 1024w, https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Prof-Dr-Koczulla-300x170.jpg 300w, https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Prof-Dr-Koczulla-768x435.jpg 768w, https://alpha1-deutschland.org/wp-content/uploads/Alpha1-Prof-Dr-Koczulla.jpg 1200w" sizes="(max-width: 1024px) 100vw, 1024px" /></div></div></div></div></div>
		</div> 
	</div> 
			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a8c8923a4801"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element" >
	<p>Two further webinars in the series will take place in the coming months: on December 6, 2023 on the topic of &quot;Working while ill&quot; and on January 10, 2024 on the topic of &quot;Need for care and planning&quot;.</p>
<p>During the webinar, participants will have the opportunity to ask the experts questions directly and exchange ideas with them. Registration is not required. We hope this information is helpful and look forward to your participation in future webinars!</p>
<p>This webinar series was created in cooperation with CSL Behring.</p>
</div>




			</div> 
		</div>
	</div> 
</div></div><p>The post <a href="https://alpha1-deutschland.org/en/webinar-reihe-alles-was-sozialrecht-ist">Webinar-Reihe: Alles, was (Sozial)Recht ist!</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Alles, was (Sozial)Recht ist</title>
		<link>https://alpha1-deutschland.org/en/alles-was-sozialrecht-ist</link>
		
		<dc:creator><![CDATA[Redaktion Alpha1 Deutschland e.V.]]></dc:creator>
		<pubDate>Sun, 18 Jun 2023 08:19:39 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Alpha1-Journal]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<guid ispermalink="false">https://alpha1-deutschland.org/?p=6460</guid>

					<description><![CDATA[<p>The post <a href="https://alpha1-deutschland.org/en/alles-was-sozialrecht-ist">Alles, was (Sozial)Recht ist</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a8c8923aa0b0"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row full-width-section"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				<div class="vc_separator wpb_content_element vc_separator_align_center vc_sep_width_100 vc_sep_border_width_5 vc_sep_pos_align_center vc_sep_color_grey wpb_content_element vc_separator-has-text" ><span class="vc_sep_holder vc_sep_holder_l"><span class="vc_sep_line"></span></span><h4>Author</h4><span class="vc_sep_holder vc_sep_holder_r"><span class="vc_sep_line"></span></span>
</div>
<div class="wpb_text_column wpb_content_element" >
	<p style="font-weight: 400;"><strong>Alpha1 Germany eV, as published in <a href="https://alpha1-deutschland.org/en/alpha1-journal/">Alpha1 Journal 1/2023</a>.</strong></p>
</div>



<div class="divider-wrap" data-alignment="default"><div style="margin-top: 25px; height: 5px; margin-bottom: 25px;" data-width="100%" data-animate="" data-animation-delay="" data-color="default" class="divider-border"></div></div>
<div class="wpb_text_column wpb_content_element" >
	<p>In cooperation with CSL Behring, we will be launching a new webinar series this fall for patients and their families with an Alpha-1 deficiency.</p>
<p>Over five dates, Ms. Nicole Scherhag, a certified social worker and supervisor (DGSv) specializing in social and psychosocial support for chronically ill people and their relatives, will inform us about new developments in social law and give us valuable tips on applying for benefits and for our everyday lives.</p>
<p>The webinars cover many topics that we encounter repeatedly in our consulting work and that often push us to the limits of our knowledge. We hope that these seminars will address and answer many questions.</p>
<p>The webinars will be moderated by Prof. Dr. Rembert Koczulla and Marion Wilkens.</p>
<p><strong><a href="https://players.brightcove.net/5838291723001/default_default/index.html?videoId=6339324846112" target="_blank" rel="noopener">To the recording of the webinar.</a></strong></p>
</div>




			</div> 
		</div>
	</div> 
</div></div><p>The post <a href="https://alpha1-deutschland.org/en/alles-was-sozialrecht-ist">Alles, was (Sozial)Recht ist</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Mitte 2021: elektronische Patientenakte (ePA) &#8211; wo stehen wir?</title>
		<link>https://alpha1-deutschland.org/en/mitte-2021-elektronische-patientenakte-epa-wo-stehen-wir</link>
		
		<dc:creator><![CDATA[Redaktion Alpha1 Deutschland e.V.]]></dc:creator>
		<pubDate>Tue, 28 Jun 2022 15:01:01 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<guid ispermalink="false">https://www.alpha1-deutschland.org/?p=5007</guid>

					<description><![CDATA[<p>The post <a href="https://alpha1-deutschland.org/en/mitte-2021-elektronische-patientenakte-epa-wo-stehen-wir">Mitte 2021: elektronische Patientenakte (ePA) &#8211; wo stehen wir?</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a8c8923add8c"  data-column-margin="default" data-midnight="dark" data-bottom-percent="3%"  class="wpb_row vc_row-fluid vc_row full-width-section"  style="padding-top: 0px; padding-bottom: calc(100vw * 0.03); "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				<div class="vc_separator wpb_content_element vc_separator_align_center vc_sep_width_100 vc_sep_border_width_5 vc_sep_pos_align_center vc_sep_color_grey wpb_content_element vc_separator-has-text" ><span class="vc_sep_holder vc_sep_holder_l"><span class="vc_sep_line"></span></span><h4>Author</h4><span class="vc_sep_holder vc_sep_holder_r"><span class="vc_sep_line"></span></span>
</div>
<div class="wpb_text_column wpb_content_element" >
	<p style="font-weight: 400;"><strong>Thomas Heimann</strong>, Member of the Board of Alpha1 Germany eV.</p>
</div>



<div class="divider-wrap" data-alignment="default"><div style="margin-top: 25px; height: 5px; margin-bottom: 25px;" data-width="100%" data-animate="" data-animation-delay="" data-color="default" class="divider-border"></div></div>
<div class="wpb_text_column wpb_content_element" >
	<p>A brief update on the status of the implementation projects for the electronic patient record (ePA).</p>
<p>In our last journal, we briefly outlined the original plan developed by the Ministry of Health in conjunction with the implementing agencies. According to this plan, the first, less functional version of the electronic patient record (ePA) was to be available by January 1, 2021, followed by the first truly usable version on January 1, 2022.</p>
<h2><span style="color: #004267;">What is the situation now, almost half a year later?</span></h2>
<p>I regularly inquired at my GP&#039;s office about the capabilities of their practice management system to populate my electronic patient record (ePA). Just recently, I was met with another eye roll. It seems they&#039;re not very good at it yet.<br />
Currently, the electronic patient record (ePA) is apparently only in a test phase with selected practices in the Berlin and Westphalia-Lippe regions. All practices are expected to be connected by July 1, 2021.</p>
<p>I read in a specialist article that of the approximately 150 practice management systems supposedly available in Germany, only a very small proportion are currently capable of transferring electronic patient record (ePA) data. The software industry seems to be lagging behind in updating its medical practices. The question arises: who can accelerate this process, and with what resources? The Ministry, the National Association of Statutory Health Insurance Physicians (KBV), or the individual physician as a contractual partner?<br />
I&#039;ve downloaded and installed my health insurance company&#039;s ePA app on my smartphone. I&#039;m currently waiting for the PIN to arrive by mail so I can use it. However, if my doctors can&#039;t yet enter information into my ePA and I can only manually upload my own old data, it feels like I&#039;m not gaining anything at all, just creating extra work.</p>
<p>The plan to make the digital vaccination record, dental bonus booklet, etc., available in the electronic patient record (ePA) from January 1st, 2022, remains interesting. Regardless of how the vaccination information is to be entered there, is this the same vaccination record that is currently being developed as a &#039;digital vaccination certificate&#039; in connection with the COVID-19 vaccination? Or will I then have two digital vaccination records?</p>
<p>I have another appointment with my pulmonologist this week. Let&#039;s see how far things have progressed. It remains exciting!</p>
</div>




			</div> 
		</div>
	</div> 
</div></div>
		<div id="fws_6a8c8923aefeb"  data-column-margin="default" data-midnight="light"  class="wpb_row vc_row-fluid vc_row has-row-bg-color"  style="padding-top: 0px; padding-bottom: 0px; --row-bg-color: #004267;"><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop using-bg-color"  style="background-color: #004267; "></div></div></div><div class="row_col_wrap_12 col span_12 light left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col padding-3-percent inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				
<div class="wpb_text_column wpb_content_element" >
	<p>Further information on the status of the patient file from the <a href="https://www.gematik.de/anwendungen/epa-fuer-alle" target="_blank" rel="noopener">You can find gematik here</a>.</p>
</div>




			</div> 
		</div>
	</div> 
</div></div><p>The post <a href="https://alpha1-deutschland.org/en/mitte-2021-elektronische-patientenakte-epa-wo-stehen-wir">Mitte 2021: elektronische Patientenakte (ePA) &#8211; wo stehen wir?</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Krankenhaus-Begleitung für Menschen mit Behinderung, die Eingliederungshilfe beziehen</title>
		<link>https://alpha1-deutschland.org/en/krankenhaus-begleitung-fuer-menschen-mit-behinderung-die-eingliederungshilfe-beziehen</link>
		
		<dc:creator><![CDATA[Redaktion Alpha1 Deutschland e.V.]]></dc:creator>
		<pubDate>Mon, 17 Jan 2022 11:25:33 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<guid ispermalink="false">https://www.alpha1-deutschland.org/?p=4769</guid>

					<description><![CDATA[<p>The post <a href="https://alpha1-deutschland.org/en/krankenhaus-begleitung-fuer-menschen-mit-behinderung-die-eingliederungshilfe-beziehen">Krankenhaus-Begleitung für Menschen mit Behinderung, die Eingliederungshilfe beziehen</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a8c8923b311c"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row full-width-section"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				<div class="vc_separator wpb_content_element vc_separator_align_center vc_sep_width_100 vc_sep_border_width_5 vc_sep_pos_align_center vc_sep_color_grey wpb_content_element vc_separator-has-text" ><span class="vc_sep_holder vc_sep_holder_l"><span class="vc_sep_line"></span></span><h4>Author</h4><span class="vc_sep_holder vc_sep_holder_r"><span class="vc_sep_line"></span></span>
</div>
<div class="wpb_text_column wpb_content_element" >
	<p style="font-weight: 400;"><b>Alpha1 Germany eV.</b></p>
</div>



<div class="divider-wrap" data-alignment="default"><div style="margin-top: 25px; height: 5px; margin-bottom: 25px;" data-width="100%" data-animate="" data-animation-delay="" data-color="default" class="divider-border"></div></div>
<div class="wpb_text_column wpb_content_element" >
	<p>From November 1, 2022, people with disabilities are allowed to bring a trusted person with them as a companion during an inpatient hospital stay. The conditions under which the accompanying person is entitled to sick pay are also addressed., <a href="https://www.der-paritaetische.de/alle-meldungen/assistenz-im-krankenhaus-fuer-menschen-mit-behinderungen-bundesrat-stimmt-regelung-zu/" target="_blank" rel="noopener">Read here</a>.</p>
</div>




			</div> 
		</div>
	</div> 
</div></div><p>The post <a href="https://alpha1-deutschland.org/en/krankenhaus-begleitung-fuer-menschen-mit-behinderung-die-eingliederungshilfe-beziehen">Krankenhaus-Begleitung für Menschen mit Behinderung, die Eingliederungshilfe beziehen</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
		<item>
		<title>Krankenkassen bezahlen wieder für ambulante Kuren</title>
		<link>https://alpha1-deutschland.org/en/krankenkassen-bezahlen-wieder-fuer-ambulante-kuren</link>
		
		<dc:creator><![CDATA[Redaktion Alpha1 Deutschland e.V.]]></dc:creator>
		<pubDate>Mon, 17 Jan 2022 11:18:05 +0000</pubDate>
				<category><![CDATA[Allgemein]]></category>
		<category><![CDATA[Rechtliches]]></category>
		<guid ispermalink="false">https://www.alpha1-deutschland.org/?p=4767</guid>

					<description><![CDATA[<p>The post <a href="https://alpha1-deutschland.org/en/krankenkassen-bezahlen-wieder-fuer-ambulante-kuren">Krankenkassen bezahlen wieder für ambulante Kuren</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></description>
										<content:encoded><![CDATA[<div id="fws_6a8c8923b6b94"  data-column-margin="default" data-midnight="dark"  class="wpb_row vc_row-fluid vc_row full-width-section"  style="padding-top: 0px; padding-bottom: 0px; "><div class="row-bg-wrap" data-bg-animation="none" data-bg-animation-delay="" data-bg-overlay="false"><div class="inner-wrap row-bg-layer" ><div class="row-bg viewport-desktop"  style=""></div></div></div><div class="row_col_wrap_12 col span_12 dark left">
	<div  class="vc_col-sm-12 wpb_column column_container vc_column_container col no-extra-padding inherit_tablet inherit_phone"  data-padding-pos="all" data-has-bg-color="false" data-bg-color="" data-bg-opacity="1" data-animation="" data-delay="0" >
		<div class="vc_column-inner" >
			<div class="wpb_wrapper">
				<div class="vc_separator wpb_content_element vc_separator_align_center vc_sep_width_100 vc_sep_border_width_5 vc_sep_pos_align_center vc_sep_color_grey wpb_content_element vc_separator-has-text" ><span class="vc_sep_holder vc_sep_holder_l"><span class="vc_sep_line"></span></span><h4>Author</h4><span class="vc_sep_holder vc_sep_holder_r"><span class="vc_sep_line"></span></span>
</div>
<div class="wpb_text_column wpb_content_element" >
	<p style="font-weight: 400;"><b>Alpha1 Germany eV.</b></p>
</div>



<div class="divider-wrap" data-alignment="default"><div style="margin-top: 25px; height: 5px; margin-bottom: 25px;" data-width="100%" data-animate="" data-animation-delay="" data-color="default" class="divider-border"></div></div>
<div class="wpb_text_column wpb_content_element" >
	<p>Since summer 2021, preventative medical treatments at health resorts and spas have once again been covered by statutory health insurance. This aims to place greater emphasis on preventative care. Health insurance companies contribute to the costs, meaning that preventative treatments are no longer solely available to those paying out of pocket. Applications are submitted in conjunction with the patient&#039;s primary care physician.</p>
<p><a href="https://www.krankenkasseninfo.de/ratgeber/nachrichten/gilt-seit-1-juli-krankenkassen-bezahlen-wieder-fuer-ambulante-kuren-61085.html" target="_blank" rel="noopener">You can find more information here.</a></p>
</div>




			</div> 
		</div>
	</div> 
</div></div><p>The post <a href="https://alpha1-deutschland.org/en/krankenkassen-bezahlen-wieder-fuer-ambulante-kuren">Krankenkassen bezahlen wieder für ambulante Kuren</a> appeared first on <a href="https://alpha1-deutschland.org/en">Ihr Online Portal für Mitglieder und Interessierte</a>.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>